Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares, rose in value, with the stock price down by -7.89% to the previous day’s close as strong demand from buyers drove the stock to $1.28.
Actively observing the price movement in the last trading, the stock closed the session at $1.39. The value of beta (5-year monthly) was 0.00. Referring to stock’s 52-week performance, its high was $4.87, and the low was $0.62. On the whole, KPTI has fluctuated by -1.91% over the past month.
With the market capitalization of Karyopharm Therapeutics Inc currently standing at about $147.86 million, investors are eagerly awaiting this quarter’s results, scheduled for May 02, 2024 – May 06, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.33, which is expected to increase to -$0.27 for fiscal year -$1.23 and then to about -$1.01 by fiscal year 2025. Data indicates that the EPS growth is expected to be 1.60% in 2025, while the next year’s EPS growth is forecast to be 17.90%.
Analysts have estimated the company’s revenue for the quarter at $34.47 million, with a low estimate of $31.7 million and a high estimate of $38.36 million. According to the average forecast, sales growth in current quarter could jump down -5.80%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $146.52 million, representing an increase of 0.30% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that KPTI’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of KPTI currently trading nearly -10.36% and 0.67% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 45.23, while the 7-day volatility ratio is showing 11.44% which for the 30-day chart, stands at 10.68%. Furthermore, Karyopharm Therapeutics Inc (KPTI)’s beta value is 0.07, and its average true range (ATR) is 0.15.
A comparison of Karyopharm Therapeutics Inc (KPTI) with its peers suggests the former has fared considerably weaker in the market. KPTI showed an intraday change of -7.89% in last session, and over the past year, it shrunk by -66.97%%.
Data on historical trading for Karyopharm Therapeutics Inc (NASDAQ:KPTI) indicates that the trading volumes over the past 10 days have averaged 0.96 million and over the past 3 months, they’ve averaged 1.77 million. According to company’s latest data on outstanding shares, there are 114.92 million shares outstanding.
Nearly 8.15% of Karyopharm Therapeutics Inc’s shares belong to company insiders and institutional investors own 66.40% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 23.13 million shares as on Mar 15, 2024, resulting in a short ratio of 14.56. According to the data, the short interest in Karyopharm Therapeutics Inc (KPTI) stood at 20.10% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 23.43 million. The stock has risen by 48.55% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the KPTI stock heading into the next quarter.
